Supplementary figure 1.
Kaplan-Meier analysis for recurrence-free survival (RFS) (A), progression-free survival (PFS) (B), overall survival (OS) (C), and cancer-specific survival (CSS) (D) in patients underwent transurethral resection of the bladder (TURB) for non-muscle invasive bladder cancer according to the preoperative systemic immune-inflammation index (SII) level.

Supplementary figure 1.
Kaplan-Meier analysis for recurrence-free survival (RFS) (A), progression-free survival (PFS) (B), overall survival (OS) (C), and cancer-specific survival (CSS) (D) in patients underwent transurethral resection of the bladder (TURB) for non-muscle invasive bladder cancer according to the preoperative systemic immune-inflammation index (SII) level.
Supplementary figure 2
Decision curve analysis (DCA) for the net-benefit of systemic immune-inflammation index (SII) in the predictive model based on age, sex, tumor size, multifocality, tumor grade, and tumor stage, for recurrence-free survival (RFS) (A), progression-free survival (PFS) (B), overall survival (OS) (C), and cancer-specific survival (CSS) (D) for patients with intermediate-risk.

Supplementary figure 2A
Supplementary figure 2B
Supplementary figure 2D